Loading...
XSTO
SERT
Market cap12mUSD
Jul 10, Last price  
0.50SEK
1D
8.97%
1Q
34.59%
Jan 2017
-90.22%
IPO
-79.85%
Name

Serstech AB

Chart & Performance

D1W1MN
XSTO:SERT chart
P/E
P/S
3.28
EPS
Div Yield, %
Shrs. gr., 5y
23.89%
Rev. gr., 5y
13.50%
Revenues
39m
-26.15%
911,497491,1181,131,8902,700,97817,496,22116,805,68110,588,10118,742,15320,488,00018,651,00017,112,00062,913,00052,262,00038,595,000
Net income
-29m
L+220.57%
-839,375-3,543,243-8,402,447-8,116,858-6,417,469-2,547,047-12,330,561-15,877,170-6,730,000-10,252,000-29,566,000715,000-9,131,000-29,271,000
CFO
-28m
L
-1,866,43300005,893,000-11,823,000-10,586,0003,558,000-628,000-13,158,0007,631,000562,000-28,015,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 2006 and headquartered in Lund, Sweden, Serstech AB is a global provider of advanced chemical identification instruments. The company's offerings include the compact, lightweight, handheld Serstech 100 Indicator, a Raman spectrometer capable of detecting a wide array of chemicals such as explosives, narcotics, toxic industrial chemicals, pharmaceuticals, and chemical warfare agents. Complementing its hardware, Serstech provides ChemDash, a centralized software platform for managing its devices. Furthermore, the product lineup features the innovative Serstech Arx and Arx+ for rapid and precise chemical substance identification, along with the Serstech SERS kit, designed for the quick detection of low-concentration substances and narcotics samples. These solutions are utilized across various critical applications, including explosives detection, CBRN (chemical, biological, radiological, nuclear) and hazmat response, narcotics analysis, and pharmaceutical quality control.
IPO date
Aug 29, 2013
Employees
20
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT